All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
At the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco, CA, USA, Sergio Rutella, from the John van Geest Cancer Research Centre, Nottingham Trent University, UK, and colleagues presented data from their study, which aimed to identify comprehensive immune profiles across the biological heterogeneity of pediatric and adult Acute Myeloid Leukemia (AML), with the aim to implement new molecularly targeted agents for patients with specific immunologic profiles of AML.
Bone Marrow (BM) samples at diagnosis from pediatric (n = 39, median age at diagnosis = 10 years) and adult (n = 28, median age at diagnosis = 55.5 years) patients with AML were collected and analyzed in this study. A total of 90 samples from de novo AML (n = 63), AML in CR (n = 18) and relapsed AML (n = 9) were analyzed on the nCounter® System (a fully automated digital platform for gene expression analysis) using the RNA Pan-Cancer Immune Profiling Panel (detects the expression of genes for 109 cell surface markers on 24 immune cell types, and > 500 immune response genes).
The authors then investigated the correlation of the transcriptomic and proteomic profiles with patient outcome.
In order to identify leukemia-immune system interaction, Digital Spatial Profiling (DSP) was used to visualize 10 BM biopsies from patients with newly diagnosed AML. It was observed that there was co-localization of CD8 T cells with FoxP3 Treg cells and PD-L1- and VISTA-expressing cell types thus suggesting “an immune landscape which is consistent with the establishment of adaptive immune resistance mechanisms of immune escape”.
The speaker, Sergio Rutella, concluded by stating that their study identified distinct immune gene profiles among children and adults with AML. They further added that immune gene expression profiles might support the rapid prediction of relapse, identify novel immune biomarkers and therapeutic targets and can be used for the development of an integrated patient stratification.
Additionally, the speaker noted that patients with immune enriched AMLs had shorter RFS and OS and thus suggested that “immune enriched AMLs might be amenable to immunotherapy approaches tailored to the BM microenvironment including blockade of co-inhibitory molecules and/or small-molecule IDO1 inhibitors.”
References